- Nachrichtendetail
-
09.05.2024 14:39:06 - dpa-AFX: *MERCK : PHASE 3 TRIAL OF KEYTRUDA PLUS CHEMOTHERAPY IN ENDOMETRIAL CANCER FAILS TO MEET MAIN GOAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 127,990 | 18.06.24 22:00:05 | +0,490 | +0,38% | 127,650 | 128,250 | 128,270 | 127,500 |
